RT Journal Article
T1 Genetic Variants Affecting Anti-VEGF Drug Response in Polypoidal Choroidal Vasculopathy Patients: A Systematic Review and Meta-Analysis
A1 Díaz-Villamarín, Xando
A1 Blánquez-Martínez, David
A1 Pozo-Agundo, Ana
A1 Pérez-Gutiérrez, Ana María
A1 Muñoz-Ávila, José Ignacio
A1 Antúnez-Rodríguez, Alba
A1 Fernández-Gómez, Ana Estefanía
A1 García-Navas, Paloma
A1 Martínez-González, Luis Javier
A1 Dávila-Fajardo, Cristina Lucía
K1 Pharmacogenetics
K1 Personalized medicine
K1 SNP
K1 Anti-VEGF
K1 Polypoidal choroidalvasculopathy
K1 Farmacogenética
K1 Medicina de precisión
K1 Polimorfismo de nucleótido simple
K1 Factor A de crecimiento endotelial vascular
K1 Neovascularización coroidal
AB Polypoidal choroidal vasculopathy (PCV) is usually regarded as a subtype of choroidal neovascularization (CNV) that is secondary to age-related macular degeneration (AMD) characterized by choroidal vessel branching, ending in polypoidal lesions. Despite their close association, PCV and neovascular AMD have shown differences, especially regarding patients' treatment response. Currently, antivascular endothelial growth factor (anti-VEGF) drugs, such as ranibizumab, bevacizumab and aflibercept, have demonstrated their efficacy in CNV patients. However, in PCV, anti-VEGF treatments have shown inconclusive results. Many genetic polymorphisms have been associated with a variable response in exudative/wet AMD patients. Thus, the aim of this study is to explore the genetic variants affecting anti-VEGF drug response in PCV patients. In this regard, we performed a systematic review and meta-analysis. We found four variants (CFH I62V, CFH Y402H, ARMS2 A69S, and HTRA1-62A/G) that have been significantly related to response. Among them, the ARMS2 A69S variant is assessed in our meta-analysis. In conclusion, in order to implement anti-VEGF pharmacogenetics in clinical routines, further studies should be performed, distinguishing physio-pathogenic circumstances between PCV and exudative AMD and the combined effect on treatment response of different genetic variants.
PB MDPI
YR 2020
FD 2020-11-12
LK http://hdl.handle.net/10668/3498
UL http://hdl.handle.net/10668/3498
LA en
NO Díaz-Villamarín X, Blánquez-Martínez D, Pozo-Agundo A, Pérez-Gutiérrez AM, Muñoz-Ávila JI, Antúnez-Rodríguez A, et al. Genetic Variants Affecting Anti-VEGF Drug Response in Polypoidal Choroidal Vasculopathy Patients: A Systematic Review and Meta-Analysis. Genes. 2020 Nov 12;11(11):1335.
DS RISalud
RD Apr 6, 2025